| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
Baylor College of Medicine, Houston, Texas 77030 [G. A., A. F., R. L., T. W.]; Pintex Pharmaceuticals, Inc., Watertown, Massachusetts 02472 [D. W., J. S., L. B.]; and Division of Hematology/Oncology, Department of Medicine; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215 [G. W., K. P. L.]
Prostate cancer (PCa) is the most common male cancer in the United States. A major challenge that remains is to predict the clinical outcome in managing PCa patients. The prolyl isomerase Pin1 has been shown to be overexpressed in some human cancer tissues and thought to be an important player in several oncogenic pathways. However, the relationship between Pin1 expression and clinical outcome of cancer patients has not been explored. In this study, we investigated the role of Pin1 in human PCa progression and its clinicopathological significance. Immunohistochemical assessment with affinity-purified polyclonal Pin1-specific antibodies was performed on formalin-fixed paraffin sections of tissue microarray composed of 580 radical prostatectomy specimens. As determined by visual semiquantitation and confirmed by automated image analysis quantitation, Pin1 expression was positively correlated with clinical stage. Furthermore, Cox survival analysis results indicated that patients with a higher Pin1 expression had a significantly higher probability of recurrence than their counterparts with low Pin1 expression, as defined by a serum prostate-specific antigen level of 
0.4 ng/ml on two consecutive occasions after radical prostatectomy. In addition, patients with high Pin1 expression had almost 4 times the risk of having earlier recurrence than those with low Pin1 expression; patients with a very high level had 8.1 times the risk of an earlier recurrence than a low Pin1 expresser. Pin1 was also an excellent predictor of recurrence in the subset of patients with Gleason score 6 or 7 when analyzed separately: a patient with high Pin1 expression had 8.6 times the risk of having earlier recurrence than one with low Pin1 expression. Pin1 expression is as good as or better than currently used postoperatively available clinicopathological parameters and potentially could be used in the preoperative setting to assist in choice of treatment. Thus, this study suggests a role for Pin1 expression as a potentially excellent prognostic marker in PCa and suggests that Pin1 may also serve as a novel therapeutic target for PCa.
This article has been cited by other articles:
|
|
 |
|
  J. Banyard, L. Bao, M. D. Hofer, D. Zurakowski, K. A. Spivey, A. S. Feldman, L. M. Hutchinson, R. Kuefer, M. A. Rubin, and B. R. Zetter Collagen XXIII Expression Is Associated with Prostate Cancer Recurrence and Distant Metastases Clin. Cancer Res., May 1, 2007; 13(9): 2634 - 2642. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Esnault, Z.-J. Shen, E. Whitesel, and J. S. Malter The Peptidyl-Prolyl Isomerase Pin1 Regulates Granulocyte-Macrophage Colony-Stimulating Factor mRNA Stability in T Lymphocytes J. Immunol., November 15, 2006; 177(10): 6999 - 7006. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. U. Agoulnik, A. Vaid, M. Nakka, M. Alvarado, W. E. Bingman III, H. Erdem, A. Frolov, C. L. Smith, G. E. Ayala, M. M. Ittmann, et al. Androgens Modulate Expression of Transcription Intermediary Factor 2, an Androgen Receptor Coactivator whose Expression Level Correlates with Early Biochemical Recurrence in Prostate Cancer Cancer Res., November 1, 2006; 66(21): 10594 - 10602. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Suizu, A. Ryo, G. Wulf, J. Lim, and K. P. Lu Pin1 Regulates Centrosome Duplication, and Its Overexpression Induces Centrosome Amplification, Chromosome Instability, and Oncogenesis Mol. Cell. Biol., February 15, 2006; 26(4): 1463 - 1479. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-Y. Chen, G. Wulf, X. Z. Zhou, M. A. Rubin, K. P. Lu, and S. P. Balk Activation of {beta}-Catenin Signaling in Prostate Cancer by Peptidyl-Prolyl Isomerase Pin1-Mediated Abrogation of the Androgen Receptor-{beta}-Catenin Interaction Mol. Cell. Biol., February 1, 2006; 26(3): 929 - 939. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. S. Yeh, B. O. Lew, and A. R. Means The Loss of PIN1 Deregulates Cyclin E and Sensitizes Mouse Embryo Fibroblasts to Genomic Instability J. Biol. Chem., January 6, 2006; 281(1): 241 - 251. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Ryo, H. Uemura, H. Ishiguro, T. Saitoh, A. Yamaguchi, K. Perrem, Y. Kubota, K. P. Lu, and I. Aoki Stable Suppression of Tumorigenicity by Pin1-Targeted RNA Interference in Prostate Cancer Clin. Cancer Res., October 15, 2005; 11(20): 7523 - 7531. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. U. Agoulnik, A. Vaid, W. E. Bingman III, H. Erdeme, A. Frolov, C. L. Smith, G. Ayala, M. M. Ittmann, and N. L. Weigel Role of SRC-1 in the Promotion of Prostate Cancer Cell Growth and Tumor Progression Cancer Res., September 1, 2005; 65(17): 7959 - 7967. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-J. Zhou, J. Yan, W. Luo, G. Ayala, S.-H. Lin, H. Erdem, M. Ittmann, S. Y. Tsai, and M.-J. Tsai SRC-3 Is Required for Prostate Cancer Cell Proliferation and Survival Cancer Res., September 1, 2005; 65(17): 7976 - 7983. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. Hong, M. S. Ryu, and I. K. Lim Phosphorylation of Serine 147 of tis21/BTG2/pc3 by p-Erk1/2 Induces Pin-1 Binding in Cytoplasm and Cell Death J. Biol. Chem., June 3, 2005; 280(22): 21256 - 21263. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. K. Witkiewicz, S. Varambally, R. Shen, R. Mehra, M. S. Sabel, D. Ghosh, A. M. Chinnaiyan, M. A. Rubin, and C. G. Kleer {alpha}-Methylacyl-CoA Racemase Protein Expression Is Associated with the Degree of Differentiation in Breast Cancer Using Quantitative Image Analysis Cancer Epidemiol. Biomarkers Prev., June 1, 2005; 14(6): 1418 - 1423. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Kwabi-Addo, J. Wang, H. Erdem, A. Vaid, P. Castro, G. Ayala, and M. Ittmann The Expression of Sprouty1, an Inhibitor of Fibroblast Growth Factor Signal Transduction, Is Decreased in Human Prostate Cancer Cancer Res., July 15, 2004; 64(14): 4728 - 4735. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Bao, A. Kimzey, G. Sauter, J. M. Sowadski, K. P. Lu, and D.-G. Wang Prevalent Overexpression of Prolyl Isomerase Pin1 in Human Cancers Am. J. Pathol., May 1, 2004; 164(5): 1727 - 1737. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
